Hybrid Antibody Technology Ltd
Hybrid Antibody Technology Ltd is a Hong Kong company, founded in 1986, dedicated to the development and practical use of co-bodies.
Co-bodies resemble two or more antibodies joined together in such a way that all can act together with enhanced specificity and effectiveness against a given foreign body. Potential applications exist in the fields of cancer treatment and laboratory diagnostics, to name but two.
The methodology is protected by US and UK patents. Hybrid Antibody Technology Ltd is prepared to issue licences to exploit this technology for specific applications, not restricted by geographical limitiations, while using the proceeds to fund further research designed to extend general and specific applications of the technology.
We are interested in receiving expressions of interest. Please contact us.